

IMAGION BIOSYSTEMS LIMITED

ASX: IBX

2 April 2026

Appendix 3H Lodged Late – Part Repayment of Convertible Note

Imagion Biosystems (ASX: IBX) (**Company** or **Imagion**), advises that it has today lodged an Appendix 3H in relation to the part repayment of convertible notes held with Mercer Street Global Opportunity Fund, LLC (Mercer Street).

The Appendix 3H was lodged later than required under the ASX Listing Rules due to an administrative oversight.

The Company confirms that the underlying transaction, being the part repayment of \$300,000 of the previously issued convertible notes, was previously disclosed to the market in an ASX announcement released on 8 January 2026.

The Company has reviewed its internal processes and procedures to ensure compliance with its continuous disclosure obligations and ASX Listing Rules going forward.

Authorisation & Additional Information

This announcement was authorised by the Board of Imagion Biosystems Limited.

Join Imagion Biosystems' Investor Hub

Stay up to date on news and announcements or interact with our team through questions and comments via *Investor Hub*. Register at investor.imagionbiosystems.com.

— ENDS —

About Imagion Biosystems

Imagion Biosystems (ASX: IBX) is a clinical-stage, medical imaging company dedicated to transforming how cancer is diagnosed and treated. The company produced and is developing clinical applications for MagSense®, a first-of-its-class MRI imaging agent that enables clinicians to detect cancer earlier and with greater precision. Advancing molecular MRI, the company is using non-radioactive, bio-safe magnetic nanoparticles to improve diagnostic certainty for a broad range of applications, including HER2+ breast cancer, prostate cancers, and ovarian cancers. For more information, visit imagionbiosystems.com.

Imagion Biosystems Limited

ASX: IBX ACN 616 305 027

Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000

imagionbiosystems.com | investor@imagionbio.com

Executive Chairman Contact Details

Bob Proulx

investor@imaginationbio.com

AU: +61 3 9692 7222

Media Enquiries & Investor Relations:

Erich Boileau, Boileau & Co.

imaginationbio@boileau.co

US : +1 (616) 786-4461

Imagination Biosystems Limited

ASX: [IBX](#) ACN 616 305 027

Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000

imaginationbiosystems.com | investor@imaginationbio.com

